CompletedPHASE2, PHASE3NCT02453308
A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
Studying Malaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Arjen Dondorp, MDMahidol Oxford Tropical Medicine Research Unit
- Intervention
- ACT(drug)
- Enrollment
- 1110 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2015 – 2018
Study locations (20)
- College of Medicine Chittagong, Rāmu, Bangladesh
- Ann Hospital, Ann Town, Burma
- Pyay hospital, Prome, Burma
- Pyin oo Lwin hospital, Pyin Oo Lwin, Burma
- Thabeikkyin hospital, Thabeikkyin, Burma
- Pailin, Pailin, Cambodia
- Preah Vihear, Preah Vihear, Cambodia
- Pursat, Pursat, Cambodia
- Ratanakiri, Ratankiri, Cambodia
- Kinshasa, Kinshasa, Democratic Republic of the Congo
- Ispat General hospital, Rourkela, Rourkela, India
- Mohanpur Community health center, Agartala, India
- Midnapore, Medinīpur, India
- Sekong, Sekong, Laos
- Phusing hospital, Phusing, Changwat Si Sa Ket, Thailand
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02453308 on ClinicalTrials.govOther trials for Malaria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07147400Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsSerum Institute of India Pvt. Ltd.
- RECRUITINGPHASE2NCT07036159A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE1NCT06735209First-in-Human PfSPZ-LARC2 Vaccination/CHMINational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantUniversity of Oxford
- ACTIVE NOT RECRUITINGNANCT06599593Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionUniversity of California, San Francisco
- RECRUITINGPHASE4NCT06860178Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West AfricaEpicentre
- RECRUITINGPHASE3NCT06923592Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and MadagascarLondon School of Hygiene and Tropical Medicine
- RECRUITINGPHASE3NCT07082205Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital DischargeLiverpool School of Tropical Medicine